Methods of treating a neurodegenerative disease in a mammal in need thereof
The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.
1. A method of treating or ameliorating a neurodegenerative disease in a mammal in need thereof, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ATP-binding cassette (“ABC”) transporter, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated or ameliorated in the mammal, wherein the disease is selected from a tauopathy and chronic traumatic encephalopathy.
2. The method of claim 1 , wherein the ABC transporter comprises at least one selected from the group consisting of P-glycoprotein (“P-gp”) and Breast Cancer Resistance Protein (“BRCP”).
3. The method of claim 1 , wherein the drug comprises at least one selected from the group consisting of ceftriaxone; celecoxib; ciliary neurotrophic factor; cobalamin; coenzyme Q; gabapentin; Hepatocyte Growth Factor (“HGF”); Insulin-like growth factor 1 (“IGF-I”); minocycline; N-acetylcysteine; nordihydroguaiaretic acid (“NDGA”); pentoxifylline; riluzole; thalidomide; topiramate; valproic acid; vascular endothelial growth factor (“VEGF”); vitamin E; benzyloxycarbonyl-Val-Ala-Asp(Ome)-fluoromethylketone (“zVAD-fmk”); a salt or solvate thereof, and mixtures thereof.
4. The method of claim 1 , wherein the inhibitor comprises at least one selected from the group consisting of elacridar; tariquidar; zosuquidar; (E)-4,4′-(2-(4-(3-ethoxyprop-1-en-1-yl)phenyl)-1H-imidazole-4,5-diyl)bis(N-isopropylaniline) (“ONT-093”); laniquidar; a salt or solvate thereof, and mixtures thereof.
5. The method of claim 1 , wherein the drug and the inhibitor are co-administered to the mammal.
6. The method of claim 5 , wherein the drug and the inhibitor are coformulated.
7. The method of claim 1 , further comprising a step of detecting at least one symptom of the neurodegenerative disease and wherein administration of the drug and the inhibitor to the mammal takes place at the time or after the detection of at least one symptom of the neurodegenerative disease.
8. The method of claim 1 , further comprising detecting the concentration of the drug from the spinal cord, wherein the mammal that is administered the drug and the inhibitor has a higher spinal cord concentration of the drug than a mammal that is administered the drug only.
9. The method of claim 1 , further comprising detecting the compound muscle action potential peak amplitude from said patient, wherein the mammal that is administered the drug and the inhibitor has a higher compound muscle action potential peak amplitude than a mammal that is administered the drug only.
10. The method of claim 1 , wherein the drug is administered to the mammal by at least one route selected from the group consisting of inhalational, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, sublingual, ophthalmic, intrathecal, intravenous and intragastrical.